The Obesity ETF SLIM
Set alert
As of Mar 12, 3:59 PM ET
- Open
- 35.36
- Prev close
- 33.25
- Mkt cap
- 11.34M
- Vol
- 6.31K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 33.00
- High
- 36.62
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 33.17
- 200-d avg
- 33.17
News
2 days ago 247wallst.com
Obesity Pipeline vs. COVID Drag: The Hidden Numbers Deciding Pfizer's Q3 Fate on Nov. 3
Pfizer (NYSE:PFE | PFE Price Prediction) reports third-quarter results before the open on Tuesday, Nov. 3. Shares have gained 25% year to date.
5 days ago globenewswire.com
Corxel US and Amanat Acquisition Corp Announce Definitive Business Combination Agreement to Create Publicly Listed Obesity-Focused Biopharmaceutical Company
BERKELEY HEIGHTS, N.J. and WESTFIELD, N.J., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Corxel Pharmaceuticals, Inc. (“Corxel US”), a clinical-stage biopharmaceutical company focused on developing innovative…
6 days ago 247wallst.com
Why Viking Therapeutics' Oral Obesity Strategy Will Be a Make-or-Break Focus on Oct. 28
Viking Therapeutics (NASDAQ:VKTX | VKTX Price Prediction) reports third-quarter results on October 28, 2026. Shares fell 41.
1 week ago globenewswire.com
Corbus Pharmaceuticals to Present Late Breaking CRB-913 Data from Canyon-1 Study at Obesity Week® 2026
NORWOOD, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced that…
1 week ago marketbeat.com
Rani Therapeutics Eyes 2027 Obesity Data as Oral Biologics Platform Advances
Rani Therapeutics NASDAQ: RANI outlined progress for its oral biologics delivery platform, including plans to advance its obesity program RT-114 and expectations for additional milestones from its…
1 week ago zacks.com
Obesity ETFs to Gain as Novo's CagriSema Shows 25% Weight Loss
Novo Nordisk's CagriSema delivers 25% weight loss in women, spotlighting three ETFs for diversified exposure to the sector's growth.
1 week ago zacks.com
Can Viking Therapeutics Carve Out a Place in the Obesity Market?
VKTX advances oral VK2735 into phase III as it explores weight maintenance and faces intensifying obesity drug competition.
1 week ago fool.com
Viking Therapeutics Just Raised $575 Million. Here's What It Means for the Obesity Stock's Next Chapter.
Multiple phase 3 trials for VK2735 are ongoing, with key results expected in 2027 to 2028. The company's future depends on VK2735's clinical success and ongoing pipeline development.
2 weeks ago 247wallst.com
A $1,000 Investment in Eli Lilly Became $18,637. The Obesity Boom Changed Everything
Eli Lilly spent most of its 150-year history as a quiet insulin maker before a single drug reshuffled the entire obesity market and turned a modest stake into a fortune that left the S&P 500 in the…
2 weeks ago zacks.com
Viking Therapeutics Starts Phase III Development of Obesity Pill
VKTX launches two phase III studies of oral VK2735 for obesity, building on phase II results showing up to 12.2% mean weight loss.
2 weeks ago prnewswire.com
Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity
SUNRISE -1 and SUNRISE-2 Studies to Evaluate Oral VK2735 in Obese Adults with and without Type 2 Diabetes SAN DIEGO, Oct. 14, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a…
2 weeks ago globenewswire.com
Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity
-- Launch follows MHLW approval of IMCIVREE for acquired hypothalamic obesity and inclusion on Japan's National Health Insurance drug price list -- -- IMCIVREE is the first approved therapy in Japan…
3 weeks ago fool.com
Eli Lilly's Obesity Business Could Become a Much Bigger Healthcare Platform
Eli Lilly (LLY -4.39%) is trying to turn blockbuster obesity drugs into something much bigger. Its path to $1,500 depends on whether new medicines, additional indications, manufacturing scale, and…
3 weeks ago prnewswire.com
Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity
Study to Explore Oral Maintenance Dosing Regimens Following Initial Weight Loss with Subcutaneous VK2735 Monthly and Every-Other-Week Subcutaneous Regimens to also be Evaluated SAN DIEGO, Oct. 6,…
1 month ago benzinga.com
Novo Nordisk Says Next-Gen Obesity Drug Reduces Food Noise, Drives Weight Loss
Novo Nordisk A/S (NYSE:NVO) on Wednesday revealed new clinical and real-world data at the 2026 European Association for the Study of Diabetes (EASD) Annual Meeting, showcasing the efficacy of its…
1 month ago marketbeat.com
Viking's Obesity Edge May Be Staying Power, Not Weight Loss
Viking Therapeutics NASDAQ: VKTX stock jumped 36% on Sept. 22. The catalyst was new maintenance data for VK2735, its GLP-1/GIP obesity candidate, which showed that patients maintained most of their…
1 month ago globenewswire.com
Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings
As reported, ART27.13 produced approximately 40% weight loss in combination with semaglutide and approximately 20% as monotherapy, comparable to semaglutide, in obese mice over four weeks
1 month ago 247wallst.com
Viking Soars Alone as Obesity Complex Shrugs at Strong GLP-1 Results
Viking Therapeutics surged more than 26% on fresh GLP-1 maintenance data while every major obesity peer from Eli Lilly to Novo Nordisk barely registered a pulse, raising a pointed question about…
1 month ago benzinga.com
Weight Loss Drug: Viking Therapeutics Says Lead Obesity Drug Shows Weight Retention with Less Frequent Dosing
Viking Therapeutics Inc. (NASDAQ:VKTX) stock surged on Tuesday after the company released positive topline results from its much-anticipated VK2735 maintenance trial.
1 month ago barrons.com
Viking Therapeutics Stock Surges 36%. It Could Challenge Lilly and Novo's Obesity Empire.
Viking Therapeutics and Roche are developing drugs for obesity and diabetes to challenge Eli Lilly and Novo Nordisk's market duopoly.